BioPharm America™ 2013 Program Overview

Win a one-to-one meeting with senior executives from big pharma. Members of the audience will have 30 seconds to pitch their company, product, technology or service to a star-studded panel of judges representing at least six pharmaceutical companies. The top picks will be selected for a second round that includes two minutes of presentation and/or Q&A time with the judges. First and second place winners will receive a full 30-minute private follow-up meeting with the panelist of their choice. Judges will receive a written summary of all participant pitches and their scores, should they wish to follow up on their own. Audience preparation notes:

Participants will be judged on the quality and effectiveness of the overall 30-second pitch. Remember, the primary goal of an elevator pitch is to spark interest for a follow-up meeting. Pre-workshop coaching is available from the moderator (contact: doug@macbiocom.com). Practice, practice, practice!

Moderator:
Douglas MacDougall – President, MacDougall Biomedical Communications

• Steven Edelson – BioCentury Publications, Inc.
• Gregor Fachinger – Bayer HealthCare
• Brian Fenton – Shire
• John Gustofson – AstraZeneca
• James O'Mara – Ironwood Pharmaceuticals
• John Sorvillo – Amgen

Share this:

There is a palpable growing interest among clinicians and disease experts ranging from oncologists to those focused on infectious disease in the progress being made in the field of immunotherapy. The number of companies working in this space continues to grow and the field includes cell-based therapies as well as antibodies and small molecules. How will this translate into partnerships with big pharma or the large-cap biotech firms? Do the companies have the infrastructure and expertise to support development of these products? Are some firms better positioned than others? Executives from the leading immunotherapy companies in addition to their counterparts in big pharma will examine all of these questions.

Moderator:
Madhusudan V. Peshwa – Executive VP, Cellular Therapies, Maxcyte

• Karin Hehenberger – CMO, Coronado Biosciences
• Randi Isaacs – Senior Director, Oncology Translational Medicine, Novartis
• Edward Lanphier – President and CEO, Sangamo BioSciences
• Ronald A. Pepin, PhD – Senior VP and CBO, Celldex Therapeutics

Share this:

Hybrid funds are springing up all around the industry of late. It's easy to see why when you look at the complementary strengths pharma companies and VCs bring to the table to launch and back new ventures that apply scientific breakthroughs to the development of new drugs. Join our panelists in examining these innovative hybrid funds more closely and discussing the effects they will have on the future of the industry, addressing key questions about who is driving these funds, how they are working and how they are measuring success.

Moderator:
Christopher J. Denn – Partner, Life Sciences, Goodwin Procter

• Reid Leonard – Managing Director, Merck Research Ventures Fund
• Ankit Mahadevia – Principal, Life Sciences, Atlas Venture
• Douglas E. Onsi – Managing Director, HealthCare Ventures

Share this:

With IPOs and acquisitions available to only a select few biotech companies, there is an increasing interest in new business models that provide investors faster paths to liquidity. A few nimble VCs and entrepreneurs are developing funds and corporate structures that may once again make private biotech companies attractive investments. Whether constructing licensing deals where VCs receive cash dividends or rethinking the corporate structure, companies changing the game have one common theme: they focus on the drug, not the company. This panel explores these nascent deal and company structures as well as innovative approaches to rethinking the drug development model.

Moderator:
Jeffrey L. Quillen – Partner, Foley Hoag

• Bruce Booth – Partner, Atlas Venture
• David J. Collier, MD – CEO, Velocity Pharmaceutical Development; Managing Director, CMEA Capital
• Tillman U. Gerngross – CEO and Co-Founder, Adimab
• Steve Tregay, PhD – Founder, President and CEO, FORMA Therapeutics

Share this:

The panelists in this session examine some of the significant deals of the last 12 months, including transactions they have been involved in, and what these deals reveal about pharma's priorities, strategy and the options available to drug development companies in need of a corporate partner. Join dealmakers from these major companies for a strategic look inside the deal.

Moderator:
Jeffrey Stewart – Associate Practice Executive, Campbell Alliance

• Martin Birkhofer – VP, Strategic Transactions, Bristol-Myers Squibb
• Steve Bryant – VP & Head of Business Development, Genmab
• Peter Condon – Executive Director, Business Development, Alexion Pharmaceuticals
• Nagesh Mahanthappa – Formerly VP, Corporate Development, Avila Therapeutics

Share this:

John Carroll, Editor-in-Chief at FierceBiotech, and a panel of executives drawn from this year's Fierce 15 will discuss the changing financial environment for biotech and how that's influencing how companies are being operated today. What does it take to be a success in today's biotech industry? Learn from the leaders.

Moderator:
John Carroll – Editor-in-Chief, FierceBiotech

Share this:

Early stage discoveries occurring in academic laboratories constitute the fount of innovation for the life sciences industry. In fact, the innovation pipeline that the pharmaceutical industry is desperately seeking lives in the discoveries coming out of academia (funded by the government). Yet, the conversion of these early stage discoveries into clinical candidates requires attaching clinical context. This panel will tackle the alignment of current translational medicine with clinical correlates necessary to advance early stage discoveries into cost effective, safe and efficacious opportunities.

Moderator:
Baruch Harris – CBO, Enlight Biosciences

• Elona Baum – General Counsel and VP, Business Development, CIRM
• Vivian Berlin – Director, Business Development, Harvard University
• Cord Dohrmann – CSO, Evotec
• Horst Domdey – Managing Director, Bio^M Biotech Cluster Development
• Tracey Mumford – Associate Director, Research Partnerships, The Michael J. Fox Foundation for Parkinson's Research

Share this:

Due to the growing market potential in places such as Asia, South America and Eastern Europe, life science companies are forced to come up with new business models that take into consideration needs of patient populations as well as healthcare systems that may be very different from Western markets. To cater to these circumstances, companies are starting to rethink their approach to drug development. Instead of developing drugs in and for Western markets and then taking them to emerging markets, can we reverse the model? Can drugs be developed and approved in markets such as China or Brazil more cheaply and more efficiently, and then be brought to US/EU markets? This panel will feature players who are rethinking and changing the paradigms of global drug development.

Moderator:
Richard Brudnick – VP and Co-Head, Business Development/M&A, Biogen Idec

• Rami Batal, PhD – Scientific Advisor, SHI Ventures
• Carlos de Sousa – VP, Head of Commercial Licensing, GLBD, Takeda Pharmaceuticals
• Mario Grieco – President for Brazil; VP for Latin America, moksha8
• James O'Mara – VP, Corporate Development, Ironwood Pharmaceuticals

Share this:

More and more companies are considering and implementing new models that will allow them to move certain R&D functions to one or more external collaborators. Since there is no universally accepted model for externalizing R&D successfully and many factors to be weighed in how to create and operationalize these programs, it is instructive to examine some of the key considerations that go into these decisions and benchmarks for success. This session will examine this issue from the perspective of big pharma as well as drug discovery firms and CROs who offer their services as part of an "external R&D solution."

Moderator:
Abbie Celniker – CEO, Eleven Biotherapeutics

• Sridaran Natesan – VP, External Innovation, Sanofi
• Caroline Rowe – Executive Director, Clinical Development Services Alliance Leader, Covance
• Richard Soll – Senior VP, Integrated Services and Head, Corporate Alliances, WuXi AppTec
• Frank Yocca – VP, Externalization, Neuroscience iMed, AstraZeneca

Share this:

How molecular diagnostics are changing the healthcare system

With all the buzz around the benefits of "personalized medicine," it is easy to lose sight of how advances in this field will impact the healthcare system. At CBT Advisors, we believe that the shift to accountable care in the US, and the worldwide need to keep healthcare costs from growing too fast, will lead to a healthcare system that looks very different from today's. New molecular diagnostics techniques are the leading edge of this movement, changing both medical practice and spending patterns. This panel will seek to address key questions such as: How do advances in molecular diagnostics and industry collaborations in this field change treatments and health outcomes? How do molecular diagnostics companies affect the healthcare system? How are they affected by a changing healthcare system?

Moderator:
Steve Dickman – CEO, CBT Advisors

• Don Hardison – President and CEO, Good Start Genetics, Inc.
• Oliver Schacht – CEO, Curetis
• Mike Webb – CEO, Allegro Diagnostics

Share this:

Open Access: What are the long-term implications for biopharma?

The open innovation movement has gained momentum as a means to address the pharmaceutical industry's productivity problem. Another openness movement, Open Access to scholarly publication, has also accelerated recently. Open Access has enormous implications for drug development as new scientific knowledge, insights, and data sets flow seamlessly to biopharma researchers and rapidly become broadly available and integrated into scientific practice. This roundtable will explore those implications and delve into practical steps for the biopharma industry to support, and benefit from, Open Access.

Moderator:
David Steinberg – Partner, PureTech Ventures

• Tom Arneman – President, Ceiba Solutions
• Colin Hill – President and CEO, GNS Healthcare
• Yaron Turpaz – VP, Informatics & Information Sciences, Research & Development Information, AstraZeneca

Share this:

Is there a downward trend in diabetes treatment innovation? And if so, what can we do about it?

Diabetes is one of the most significant health issues today and continues, despite major treatment advances, to warrant new, novel therapies to further help patients gain better control of their disease. As in the past, such innovations are likely to originate from academic research institutions. A recent survey sponsored by Novo Nordisk and conducted by Thomson Reuters indicates that biologic therapeutics innovation is showing a downward trend. Thus, many of us are concerned about the status of research in this area.

Moderator:
Tomas Landh – Director, Strategy and Sourcing, Diabetes Research Unit, Novo Nordisk

• John L. Brooks III – President and CEO, Joslin Diabetes Center
• Steven M. Ferguson – Deputy Director, Licensing & Entrepreneurship, Office of Technology Transfer, National Institutes of Health
• Imran Nasrullah – Head, Strategic Alliances, T1D Exchange
• Thomas E. Shrader – Director, Strategic Corporate Partnerships, Office of Cooperative Research, Yale University
• Willem "Pim" Stemmer – CEO, Amunix

Share this:

Attendance for this session is limited to the first 200 people who register here

This first SciBX Summit will focus on macrocycles and constrained peptides—challenges and applications. In particular, the summit will focus the discussion around the opportunities afforded by these compounds in the area of targeting intracellular protein-protein interactions vis-à-vis small molecules and other chemical entities. Their potential for improved oral bioavailability and related benefits will also be discussed. The summit will consist of a plenary panel discussion featuring stakeholders in the space from biotech, pharma and academia.

Moderators:
Gaspar Taroncher-Oldenburg, PhD – Managing Editor and Associate Publisher, Science-Business eXchange
Joanne Kotz, PhD – Senior Editor, Science-Business eXchange
Chris Cain, PhD – Senior Writer, Science-Business eXchange

• Bruce Booth – Partner, Atlas Venture
• Spiros Liras – VP, Cardiovascular and Metabolic Diseases, Medicinal Chemistry, Pfizer
• Barry A. Morgan – VP, Molecular Discovery Research, GlaxoSmithKline
• Patrick Reid – CSO, PeptiDream
• Tomi Sawyer – CSO, Aileron Therapeutics
• Greg Verdine – Erving Professor, Harvard University; Venture Partner, Third Rock Ventures

Share this: